{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:17:55Z","timestamp":1793636275757,"version":"4.5.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"DOI":"10.7759\/cureus.96833","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:07:12Z","timestamp":1763136432000},"source":"Crossref","is-referenced-by-count":1,"title":["Knowledge and Adherence to Alendronate Administration Among Postmenopausal Osteoporosis Patients: A Cross-Sectional Study From a Tertiary Care Facility in Colombo South"],"prefix":"10.7759","author":[{"given":"Jenifar","family":"Prashanthan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirthanathan","family":"Prashanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjala","family":"Meegoda Widanege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaminda","family":"Garusinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston J","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, et al.. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017, 12:43. 10.1007\/s11657-017-0324-5","journal-title":"Arch Osteoporos"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s4870","article-title":"Regimen complexity and medication nonadherence in elderly patients","volume":"5","author":"Corsonello A","year":"2009","unstructured":"Corsonello A, Pedone C, Lattanzio F, et al.. Regimen complexity and medication nonadherence in elderly patients. Ther Clin Risk Manag. 2009, 5:209-16. 10.2147\/tcrm.s4870","journal-title":"Ther Clin Risk Manag"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell R","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, et al.. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019, 104:1595-622. 10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.05.004","article-title":"Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis","volume":"37","author":"Felsenberg D","year":"2005","unstructured":"Felsenberg D, Miller P, Armbrecht G, et al.. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone. 2005, 37:651-4. 10.1016\/j.bone.2005.05.004","journal-title":"Bone"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton B","year":"2003","unstructured":"Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003, 14:259-62. 10.1007\/s00198-002-1370-3","journal-title":"Osteoporos Int"},{"key":"ref6","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman AB","year":"2002","unstructured":"Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ. 2002, 166:1426-30.","journal-title":"CMAJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz I","year":"2010","unstructured":"Imaz I, Zegarra P, Gonz\u00e1lez-Enr\u00edquez J, et al.. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010, 21:1943-51. 10.1007\/s00198-009-1134-4","journal-title":"Osteoporos Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-007-0768-6","article-title":"Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate","volume":"25","author":"Kamatari M","year":"2007","unstructured":"Kamatari M, Koto S, Ozawa N, et al.. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007, 25:302-9. 10.1007\/s00774-007-0768-6","journal-title":"J Bone Miner Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2307\/2290547","article-title":"Sample size determination in health studies: a practical manual","volume":"86","author":"Lachenbruch PA","year":"1991","unstructured":"Lachenbruch PA, Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual. J Am Stat Assoc. 1991, 86:1149. 10.2307\/2290547","journal-title":"J Am Stat Assoc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2010.01210.x","article-title":"Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women","volume":"36","author":"Lai PS","year":"2011","unstructured":"Lai PS, Chua SS, Chew YY, Chan SP. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther. 2011, 36:557-67. 10.1111\/j.1365-2710.2010.01210.x","journal-title":"J Clin Pharm Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001, 285:785-95. 10.1001\/jama.285.6.785","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-022-01690-5","article-title":"Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine","volume":"22","author":"Radwan A","year":"2022","unstructured":"Radwan A, Shraim N, Elaraj J, et al.. Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine. BMC Womens Health. 2022, 22:105. 10.1186\/s12905-022-01690-5","journal-title":"BMC Womens Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis","volume":"89","author":"Rizzoli R","year":"2011","unstructured":"Rizzoli R, Reginster JY, Boonen S, et al.. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011, 89:91-104. 10.1007\/s00223-011-9499-8","journal-title":"Calcif Tissue Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-006-0073-6","article-title":"Determinants of adherence to osteoporosis treatment in clinical practice","volume":"17","author":"Rossini M","year":"2006","unstructured":"Rossini M, Bianchi G, Di Munno O, et al.. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006, 17:914-21. 10.1007\/s00198-006-0073-6","journal-title":"Osteoporos Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2013.34575","article-title":"The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy","volume":"9","author":"Sewerynek E","year":"2013","unstructured":"Sewerynek E, Horst-Sikorska H, St\u0119pie\u0144-K\u0142os W, et al.. The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy. Arch Med Sci. 2013, 9:288-96. 10.5114\/aoms.2013.34575","journal-title":"Arch Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e31815a9685","article-title":"Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies","volume":"100","author":"Silverman SL","year":"2007","unstructured":"Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J. 2007, 100:1214-8. 10.1097\/SMJ.0b013e31815a9685","journal-title":"South Med J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2014.995164","article-title":"Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter","volume":"18","author":"Vytrisalova M","year":"2015","unstructured":"Vytrisalova M, Touskova T, Ladova K, et al.. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. Climacteric. 2015, 18:608-16. 10.3109\/13697137.2014.995164","journal-title":"Climacteric"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/428305-knowledge-and-adherence-to-alendronate-administration-among-postmenopausal-osteoporosis-patients-a-cross-sectional-study-from-a-tertiary-care-facility-in-colombo-south","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:07:13Z","timestamp":1763136433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/428305-knowledge-and-adherence-to-alendronate-administration-among-postmenopausal-osteoporosis-patients-a-cross-sectional-study-from-a-tertiary-care-facility-in-colombo-south"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.96833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}